Latest Articles
-
Pfizer Doing Well, But Some Challenges Are On The Horizon
Pfizer (NYSE:PFE) missed consensus estimates when it reported its Q4 2016 earnings. Some of it can be attributed to below par performance from the Prevnar vaccine and greater than expected competition from generics for drugs that have gone off-p...
-
Pfizer Earnings Preview: Expect Moderate Growth As Ibrance, Eliquis Ramp Up
Pfizer (NYSE:PFE) saw a revival in its growth in the first nine months of 2016. We expect this trend to continue when the company reports its Q4 2016 results tomorrow. While sales of several of its drugs are under pressure due to the competition...
-
Despite Failed Allergan Bid, Pfizer Can Not Complain About 2016
The year 2016 was a transformative one for Pfizer ‘s (NYSE:PFE) business. The company managed to turn around its revenue growth after nearly 5 years of consistent decline. Despite the failed Allergan deal, it regained investor confidence w...
-
Pfizer May Be Happy With Anacor
It is no secret that Pfizer (NYSE:PFE) has traditionally relied on acquisitions to a great extent to bolster its growth and drug pipeline. The company acquired Hospira last year and this year completed the acquisition of Anacor and Medivation. ...
-
Avelumab Granted Priority Review: One Of The Many Milestones That Pfizer Needs
Pfizer (NYSE:PFE) has been co-developing an anti-PD L1 cancer drug Avelumab with Merck KGaA, which has now been granted priority review status by the FDA. This puts the drug on track to hit the market somewhere in 2017, which is in line with our...
-
Estimating Value Of Pfizer’s Consumer Health Business Amid Rumours Of Sale/Spin-off
According to a report by Reuters, Pfizer Inc. (NYSE: PFE) management is considering the potential sale or spin-off of its consumer health business. While the article reports that the value of the business is estimated to be around $14 billion. ...
-
Pfizer Q3 Earnings Review: Performance On Expected Lines, Future Outlook Is Stable
Pfizer Inc. (NYSE: PFE) recently reported its Q3’16 earnings and posted operational revenue growth of 3% (excluding legacy Hospira) which was on expected lines. For the next quarter, we believe Pfizer will maintain low single digit growth as the...
-
Pfizer’s Q3 Earnings Preview: It Is More About Long-term
Pfizer Inc. (NYSE: PFE) is set to report its Q3’16 earnings on November 1st. The company reported revenue growth of 4% last quarter on year-over-year basis, excluding Hospira which it acquired in September last fiscal year. Although Pfizer has a...
-
Pfizer Divests Hospira Infusion Systems To ICU, Retaining An Interest In The Acquier
Pfizer Inc. (NYSE: PFE) recently announced that it has entered into definitive agreement with ICU Medical (NASDAQ: ICUI) to sell its infusion systems business, which it had received via the acquisition of Hospira last year. The deal is expected t...
-
Potential 10% Upside To Pfizer’s Price Estimate
Our estimate for Pfizer (NYSE:PFE) is dependent on the success of its phase 3 pipeline. Here, we consider an extreme scenario in which all phase 3 drugs are approved within next 3 years. It could imply 10% upside to our price estimate. Phase 3 p...
-
Oncology & Biosimilars To Be Growth Engines For Pfizer
Pfizer (NYSE:PFE) reported its Q2 results on Tuesday, August 2th, with 11% increase in revenue and 14% increase in EPS as compared to last year. We believe oncology and biosimilars to be growth engines for Pfizer in coming quarters. The oncology...
-
What Can We Expect From PFE Q2 Earnings?
Source: [1] Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020, Allied Market Research, Sourced on July 26,2016 Have more questions about Pfizer? See the links below. By What Percentage Did Pfizer&#...
-
Can Pfizer Acquisition Of Anacore Be Justified?
Here Is Why Pfizer Acquired Anacore Pharmaceuticals Pfizer made failed attempts to acquire AstraZeneca and Allergan. The deals were aimed at tax synergies. Changes in US acquisition laws makes such acquisitions difficult. As a result, Pfize...
-
Key Takeaways From Pfizer’s Earnings
Pfizer’s Q1 2016 earnings re-affirmed our bullish stance on the stock. We have upgraded our price estimate to $37 per share. Here are the key takeaways from the earnings that investors should keep in mind. Takeaway 1: Pfizer̵...
-
Will Pfizer Answer These Two Questions In Its First Quarter Earnings?
Pfizer will report its Q1 2016 earnings on May 3rd, 2016. What can we expect? Here is what we believe are the key questions to which investors will seek answers. Can Pfizer Revive Its Growth After Years Of Decline? Pfizer’s revenues hav...
